Retatrutide, a triple agonist targeting GLP-1, GIP and glucagon receptors, has shown up to 24% body-weight reduction in phase-2 trials — the highest reported among incretin therapies so far. It is not yet FDA approved and GI side effects remain common. Talk to your care team before considering any GLP-1 therapy.
